Personalised Breast Cancer Programme (PBCP) in UK Using Gene Analysis to Potentially Guide Treatment Decisions

Chinese Biotech’s Herceptin Biosimilar Meets Endpoint & Moves Closer to Approval TrialsiteN

Dr Jean Abraham co-leads the Personalised Breast Cancer Programme (PBCP), a collaboration between Cancer Research UK and Addenbrooke’s Charitable Trust. It has analysed the genes of 600 breast cancer patients to see if they could do this quickly enough to use the information to guide treatment decisions.

These same breast cancer patients are also involved in clinical trials aiming to understand why some respond to treatment while others don’t, by examining the genetic details of their individual cancers. “The real drive is to identify those who would benefit from treatment and spare treatment from those who don’t need it,” says Abraham, who believes the programme is already making a difference.

“It’s led to changes in treatment decisions which in turn has prevented severe toxicities in some patients as they’ve managed to avoid drugs which they may have had problems handling. It has also led to the screening of patients’ families due to previously unknown inherited cancer risk,” she says.

Results This Far

For most patients, the results confirmed that they were receiving the best treatment available. But a small number (15 in 100) were found to be better suited to a different drug, and over half (more than 60 in 100) were found to be potentially eligible for a clinical trial should their cancer come back in the future. “The beauty of the sequencing project is that we are getting the data faster and can react,” Abraham says.

Over the next 5 years the team aim to recruit 1650 more patients across the UK.

Additional Research from the Cancer Research UK Cambridge Institute

Dr Alejandra Bruna, from the Cancer Research UK Cambridge Institute, transplants tumour samples taken directly from a patient during surgery into mice, aiming to recreate the complexity of the patient’s cancer in these so-called ‘avatars’. These avatars are an attempt to develop more representative techniques.

So far, she’s grown tumours from more than 100 breast cancer patients in mice, showing that they’re very similar to the patient’s original tumour. “We have shown that when you put a tumour in the avatar mouse that the tumour retains all the molecular features that that tumour has in the human,” reports Bruna. They’ve then gone a step further. “We’ve tested how that specific tumour responds to hundreds of different therapies,” she says. And this is the power of the technique – patients can only be treated in one way at a time, but different treatments can be tested in multiple mice.

She hopes that the information from these studies could help guide clinical decision making for patients in the future. Currently they’re testing whether drug responses and the tumour’s behaviour are the same in the patient as their very own avatars.  The next goal would be to run a clinical trial to test whether avatars could be used to predict which future therapies would work best in patients whose disease has returned. This would help doctors and patients make a more informed choice, as right now there’s not a huge amount of evidence for what treatment to use when cancer comes back.

Future Research Plans

There’s a lot more to do, reports Cancer Research UK, such as setting up a clinical trial to see if using the information on avatars will benefit patients. They also need to refine which patients these avatars could help most, possibly focusing on a subset of patients with fewer treatment options. Bruna and Abraham are hopeful this will move quickly, largely because patients have been so generous in supporting the work.

“Time and time again I’m struck by how willingly, at a very vulnerable moment in their lives, shortly after being diagnosed, patients will commit to help with multiple research projects largely to help those who come after them,” Abraham says. “This study and its legacy is really down to them.”

Call to Action: Do you live in the UK and have a breast cancer diagnosis? This study is currently recruiting participants! Reach out to Trialsite News if you are interested, as we can help initiate a connection with the investigators and universities involved.